Carys Barton

ESC 2024 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care. Trials covered in detail include: FINE-HEART HELIOS-B RESHAPE-HF2 Recorded on-site at ESC Congress 2024, London. Editors: Jordan Rance and Mirjam Boros. Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF. Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.

ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF. Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer). FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical trials evaluating finerenone, a mineralocorticoid receptor antagonist (MRA).